257 related articles for article (PubMed ID: 25866250)
1. Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment.
Coppolino G; Lucisano S; Rivoli L; Fuiano G; Villari A; Villari I; Leonello G; Lacquaniti A; Santoro D; Buemi M
Ther Apher Dial; 2015 Oct; 19(5):471-6. PubMed ID: 25866250
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
Yaguchi A; Yonekubo S; Maruyama I; Tatemichi S; Maruyama K; Kobayashi M
Drug Res (Stuttg); 2016 May; 66(5):262-9. PubMed ID: 26761712
[TBL] [Abstract][Full Text] [Related]
3. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
Autissier V; Damment SJ; Henderson RA
J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
[TBL] [Abstract][Full Text] [Related]
4. Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
Schumacher SP; Schurgers LJ; Vervloet MG; Neradova A
Nephrology (Carlton); 2019 Feb; 24(2):221-226. PubMed ID: 29479762
[TBL] [Abstract][Full Text] [Related]
5. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Keith MS; Wilson RJ; Preston P; Copley JB
Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Zhou T; Li H; Xie W; Lin Z
Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
[TBL] [Abstract][Full Text] [Related]
7. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
8. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
[TBL] [Abstract][Full Text] [Related]
9. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
Wilson RJ; Keith MS; Preston P; Copley JB
Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
[TBL] [Abstract][Full Text] [Related]
10. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of the phosphate binder, lanthanum carbonate.
Damment SJ
Ren Fail; 2011; 33(2):217-24. PubMed ID: 21332344
[TBL] [Abstract][Full Text] [Related]
12. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
Noto L
J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
[TBL] [Abstract][Full Text] [Related]
13. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Sprague SM; Ross EA; Nath SD; Zhang P; Pratt RD; Krause R
Clin Nephrol; 2009 Oct; 72(4):252-8. PubMed ID: 19825330
[TBL] [Abstract][Full Text] [Related]
14. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
Lai B; Cervelli MJ
Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
16. Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.
Filiopoulos V; Koutis I; Trompouki S; Hadjiyannakos D; Lazarou D; Vlassopoulos D
Ther Apher Dial; 2011 Feb; 15(1):20-7. PubMed ID: 21272248
[TBL] [Abstract][Full Text] [Related]
17. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
[TBL] [Abstract][Full Text] [Related]
18. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
Martin P; Wang P; Robinson A; Poole L; Dragone J; Smyth M; Pratt R
Am J Kidney Dis; 2011 May; 57(5):700-6. PubMed ID: 21354682
[TBL] [Abstract][Full Text] [Related]
19. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
[TBL] [Abstract][Full Text] [Related]
20. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
Wilson R; Zhang P; Smyth M; Pratt R
Curr Med Res Opin; 2009 Dec; 25(12):3021-8. PubMed ID: 19845495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
